Grossman Alon, Weiss Avraham, Koren-Morag Nira, Shimon Ilan, Beloosesky Yichayaou, Meyerovitch Joseph
Unit of Endocrinology and Metabolism, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Israel; Department of Geriatrics, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel.
Am J Med. 2016 Apr;129(4):423-30. doi: 10.1016/j.amjmed.2015.11.027. Epub 2015 Dec 20.
The association between subclinical hypothyroidism and hyperthyroidism and mortality in the elderly is poorly defined. This study was designed to evaluate the association between subclinical hypothyroidism and subclinical hyperthyroidism and mortality in the elderly and to define the thyroid-stimulating hormone values associated with excess mortality in the elderly.
We performed a retrospective cohort study with a review of a computerized database of a large health care organization. Patients aged more than 65 years evaluated in the years 2002 to 2012 with documented normal free T4 values were included in the analysis. All cases of known thyroid disease or cases in which thyroid medications were dispensed were excluded. Analysis was performed only on individuals who were not treated for hyperthyroidism or hypothyroidism during the follow-up period. Subjects were divided into 3 groups based on thyroid-stimulating hormone values: normal (normal thyroid-stimulating hormone), subclinical hypothyroidism (thyroid-stimulating hormone >4.2 mIU/L), and subclinical hyperthyroidism (thyroid-stimulating hormone <0.35 mIU/L). All-cause mortality hazard ratio (HR) was compared among the 3 groups, and a subanalysis according to thyroid-stimulating hormone values was performed in those with subclinical hypothyroidism and subclinical hyperthyroidism.
A final analysis was performed on 17,440 individuals with subclinical thyroid disease (538 with subclinical hyperthyroidism [3.1%], 1956 with subclinical hypothyroidism [11.2%], 14,946 normal cases [85.7%], average age of 83 years, 10,289 were women) who were followed up for 10 years. Both subclinical hypothyroidism (HR, 1.75; confidence interval [CI], 1.63-1.88) and subclinical hyperthyroidism (HR, 2.33; CI, 2.08-2.63) were associated with significantly increased mortality, and this association persisted on multivariate analysis (subclinical hypothyroidism HR, 1.68; CI, 1.56-1.8, subclinical hyperthyroidism HR, 1.93; CI, 1.7-2.17). Crude mortality was elevated at 1, 2, and 5 years, but this association seemed to decrease as time from initial analysis increased (most significant association at 1 year). Thyroid-stimulating hormone values greater than 6.38 mIU/L were associated with the highest mortality in those with subclinical hypothyroidism after multivariate adjustment (HR, 1.708; CI, 1.38-2.12), whereas in subclinical hyperthyroidism, no threshold for increased mortality was identified. Mortality was higher.
Both subclinical hypothyroidism and subclinical hyperthyroidism are associated with increased mortality in the elderly. A threshold thyroid-stimulating hormone value (>6.35 mIU/L) exists for increased mortality in subclinical hypothyroidism, but not in subclinical hyperthyroidism.
亚临床甲状腺功能减退和甲状腺功能亢进与老年人死亡率之间的关联尚不明确。本研究旨在评估亚临床甲状腺功能减退和亚临床甲状腺功能亢进与老年人死亡率之间的关联,并确定与老年人额外死亡率相关的促甲状腺激素值。
我们进行了一项回顾性队列研究,回顾了一个大型医疗保健组织的计算机化数据库。纳入分析的患者为2002年至2012年间年龄超过65岁且游离T4值记录正常的患者。排除所有已知甲状腺疾病病例或开具甲状腺药物的病例。仅对随访期间未接受甲状腺功能亢进或甲状腺功能减退治疗的个体进行分析。根据促甲状腺激素值将受试者分为3组:正常(促甲状腺激素正常)、亚临床甲状腺功能减退(促甲状腺激素>4.2 mIU/L)和亚临床甲状腺功能亢进(促甲状腺激素<0.35 mIU/L)。比较3组之间的全因死亡率风险比(HR),并对亚临床甲状腺功能减退和亚临床甲状腺功能亢进患者根据促甲状腺激素值进行亚组分析。
对17440例亚临床甲状腺疾病患者(538例亚临床甲状腺功能亢进[3.1%],1956例亚临床甲状腺功能减退[11.2%],14946例正常病例[85.7%],平均年龄83岁,10289例为女性)进行了为期10年的随访,最终进行了分析。亚临床甲状腺功能减退(HR,1.75;置信区间[CI],1.63 - 1.88)和亚临床甲状腺功能亢进(HR,2.33;CI,2.08 - 2.63)均与死亡率显著增加相关,且这种关联在多变量分析中持续存在(亚临床甲状腺功能减退HR,1.68;CI,1.56 - 1.8,亚临床甲状腺功能亢进HR,1.93;CI,1.7 - 2.17)。1年、2年和5年时的粗死亡率升高,但随着距初始分析时间的增加,这种关联似乎减弱(1年时关联最显著)。多变量调整后,促甲状腺激素值大于6.38 mIU/L与亚临床甲状腺功能减退患者的最高死亡率相关(HR,1.708;CI,1.38 - 2.12),而在亚临床甲状腺功能亢进患者中,未发现死亡率增加的阈值。死亡率更高。
亚临床甲状腺功能减退和亚临床甲状腺功能亢进均与老年人死亡率增加相关。亚临床甲状腺功能减退存在死亡率增加的促甲状腺激素阈值(>6.35 mIU/L),而亚临床甲状腺功能亢进则不存在。